Stock Track | Burning Rock Soars on NMPA Approval for Co-Developed Lung Cancer Companion Diagnostic

Stock Track10-11

Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 15% in pre-market trading on October 11th, 2024, following a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.

Burning Rock and its partner, biopharmaceutical firm Dizal, jointly announced that the National Medical Products Administration (NMPA) of China has granted marketing approval to their Next-Generation Sequencing (NGS)-based companion diagnostic test called "LungCure CDx." This test is designed to detect EGFR exon 20 insertion mutations in non-small cell lung cancer patients and is intended to be used in conjunction with Dizal's EGFR exon 20 insertion mutation-targeted therapy, sunvozertinib.

The approval marks a significant milestone, as LungCure CDx is the first co-developed NGS-based companion diagnostic for lung cancer to receive NMPA clearance since the release of China's companion diagnostic guidelines. This regulatory approval highlights the successful collaboration between Burning Rock and Dizal, and paves the way for a precision treatment solution for lung cancer patients with this specific mutation in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133138899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-11 16:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133138899","market":"hk","top_or_hot":-1,"title":"Stock Track | Burning Rock Soars on NMPA Approval for Co-Developed Lung Cancer Companion Diagnostic","media":"Stock Track","content":"<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 15% in pre-market trading on October 11th, 2024, following a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.</p>\n\n<p>Burning Rock and its partner, biopharmaceutical firm Dizal, jointly announced that the National Medical Products Administration (NMPA) of China has granted marketing approval to their Next-Generation Sequencing (NGS)-based companion diagnostic test called \"LungCure CDx.\" This test is designed to detect EGFR exon 20 insertion mutations in non-small cell lung cancer patients and is intended to be used in conjunction with Dizal's EGFR exon 20 insertion mutation-targeted therapy, sunvozertinib.</p>\n\n<p>The approval marks a significant milestone, as LungCure CDx is the first co-developed NGS-based companion diagnostic for lung cancer to receive NMPA clearance since the release of China's companion diagnostic guidelines. This regulatory approval highlights the successful collaboration between Burning Rock and Dizal, and paves the way for a precision treatment solution for lung cancer patients with this specific mutation in China.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Burning Rock Soars on NMPA Approval for Co-Developed Lung Cancer Companion Diagnostic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Burning Rock Soars on NMPA Approval for Co-Developed Lung Cancer Companion Diagnostic\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-11 16:20 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 15% in pre-market trading on October 11th, 2024, following a significant regulatory approval for its co-developed companion diagnostic ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNR","symbol_name":"燃石医学","start_time":0,"source_url":"","article_id":"1133138899","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133138899","pubTimestamp":1728634816,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Burning Rock Biotech Limited  surged over 15% in pre-market trading on October 11th, 2024, following a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.Burning Rock and its partner, biopharmaceutical firm Dizal, jointly announced that the National Medical Products Administration  of China has granted marketing approval to their Next-Generation Sequencing -based companion diagnostic test called \"LungCure CDx.\" This test is designed to detect","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNR":"燃石医学"},"translate_title":"股票赛道Burning Rock因NMPA批准共同开发的肺癌伴随诊断而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNR":1},"content_text":"Shares of Burning Rock Biotech Limited (NASDAQ: BNR) surged over 15% in pre-market trading on October 11th, 2024, following a significant regulatory approval for its co-developed companion diagnostic test for lung cancer.\nBurning Rock and its partner, biopharmaceutical firm Dizal, jointly announced that the National Medical Products Administration (NMPA) of China has granted marketing approval to their Next-Generation Sequencing (NGS)-based companion diagnostic test called \"LungCure CDx.\" This test is designed to detect EGFR exon 20 insertion mutations in non-small cell lung cancer patients and is intended to be used in conjunction with Dizal's EGFR exon 20 insertion mutation-targeted therapy, sunvozertinib.\nThe approval marks a significant milestone, as LungCure CDx is the first co-developed NGS-based companion diagnostic for lung cancer to receive NMPA clearance since the release of China's companion diagnostic guidelines. This regulatory approval highlights the successful collaboration between Burning Rock and Dizal, and paves the way for a precision treatment solution for lung cancer patients with this specific mutation in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133138899"}